127. Frontotemporal lobar degeneration Clinical trials / Disease details
Clinical trials : 90 / Drugs : 87 - (DrugBank : 30) / Drug target genes : 39 - Drug target pathways : 88
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02736695 (ClinicalTrials.gov) | July 2016 | 7/4/2016 | Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia | Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and FTD | Primary Progressive Aphasia;Behavioral Variant of Frontotemporal Dementia;Frontotemporal Dementia, Behavioral Variant | Drug: F-18 AV 1451 | Mayo Clinic | NULL | Recruiting | 18 Years | N/A | All | 200 | N/A | United States |